{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:43:19Z","timestamp":1787020999808,"version":"build-2736575974"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm Regener"],"DOI":"10.1186\/s41232-025-00395-0","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T08:43:58Z","timestamp":1759999438000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Recent advances in immunological mechanisms and murine disease models of idiopathic inflammatory myopathies"],"prefix":"10.1186","volume":"45","author":[{"given":"Akiko","family":"Nishidate","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Piruzyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manami","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzo","family":"Koda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"issue":"1","key":"395_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41572-021-00321-x","volume":"7","author":"IE Lundberg","year":"2021","unstructured":"Lundberg IE, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Christopher-Stine L, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021;7(1):87.","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"395_CR2","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1474-4422(07)70171-0","volume":"6","author":"M Needham","year":"2007","unstructured":"Needham M, Mastaglia FL. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol. 2007;6(7):620\u201331.","journal-title":"Lancet Neurol"},{"issue":"4","key":"395_CR3","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1067\/mjd.2002.120621","volume":"46","author":"RD Sontheimer","year":"2002","unstructured":"Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002;46(4):626\u201336.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"395_CR4","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41584-020-00515-9","volume":"16","author":"Y Allenbach","year":"2020","unstructured":"Allenbach Y, Benveniste O, Stenzel W, Boyer O. Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nat Rev Rheumatol. 2020;16(12):689\u2013701.","journal-title":"Nat Rev Rheumatol"},{"issue":"18","key":"395_CR5","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1056\/NEJMra1402225","volume":"372","author":"MC Dalakas","year":"2015","unstructured":"Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015;372(18):1734\u201347.","journal-title":"N Engl J Med"},{"issue":"2","key":"395_CR6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/nrrheum.2017.1","volume":"13","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE. Myositis in 2016: new tools for diagnosis and therapy. Nat Rev Rheumatol. 2017;13(2):74\u20136.","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"395_CR7","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0889-857X(02)00022-4","volume":"28","author":"RL Wortmann","year":"2002","unstructured":"Wortmann RL, DiMauro S. Differentiating idiopathic inflammatory myopathies from metabolic myopathies. Rheum Dis Clin North Am. 2002;28(4):759\u201378.","journal-title":"Rheum Dis Clin North Am"},{"issue":"12","key":"395_CR8","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1002\/art.40320","volume":"69","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, Tjarnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, et al. 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol. 2017;69(12):2271\u201382.","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"395_CR9","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1136\/annrheumdis-2019-216599","volume":"79","author":"I Pinal-Fernandez","year":"2020","unstructured":"Pinal-Fernandez I, Casal-Dominguez M, Derfoul A, Pak K, Miller FW, Milisenda JC, et al. Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis. Ann Rheum Dis. 2020;79(9):1234\u201342.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"395_CR10","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/s10067-021-06035-5","volume":"41","author":"K Wang","year":"2022","unstructured":"Wang K, Zhu R, Li J, Zhang Z, Wen X, Chen H, et al. Coexpression network analysis coupled with connectivity map database mining reveals novel genetic biomarkers and potential therapeutic drugs for polymyositis. Clin Rheumatol. 2022;41(6):1719\u201330.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"395_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00401-023-02669-8","volume":"147","author":"C Nelke","year":"2024","unstructured":"Nelke C, Schmid S, Kleefeld F, Schroeter CB, Goebel HH, Hoffmann S, et al. Complement and MHC patterns can provide the diagnostic framework for inflammatory neuromuscular diseases. Acta Neuropathol. 2024;147(1):15.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"395_CR12","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/00002281-199411000-00004","volume":"6","author":"R Mantegazza","year":"1994","unstructured":"Mantegazza R, Bernasconi P. Cellular aspects of myositis. Curr Opin Rheumatol. 1994;6(6):568\u201374.","journal-title":"Curr Opin Rheumatol"},{"key":"395_CR13","doi-asserted-by":"publisher","first-page":"1169057","DOI":"10.3389\/fimmu.2023.1169057","volume":"14","author":"M Li","year":"2023","unstructured":"Li M, Zhang Y, Zhang W, Sun J, Liu R, Pan Z, et al. Type 1 interferon signature in peripheral blood mononuclear cells and monocytes of idiopathic inflammatory myopathy patients with different myositis-specific autoantibodies. Front Immunol. 2023;14:1169057.","journal-title":"Front Immunol"},{"issue":"1","key":"395_CR14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s12016-025-09047-0","volume":"68","author":"T Liu","year":"2025","unstructured":"Liu T, Chen B, Yin G, Xie Q. Targeting B cells for the treatment of idiopathic inflammatory myopathy. Clin Rev Allergy Immunol. 2025;68(1):40.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"395_CR15","doi-asserted-by":"publisher","first-page":"103334","DOI":"10.1016\/j.autrev.2023.103334","volume":"22","author":"M Gasparotto","year":"2023","unstructured":"Gasparotto M, Franco C, Zanatta E, Ghirardello A, Zen M, Iaccarino L, et al. The interferon in idiopathic inflammatory myopathies: different signatures and new therapeutic perspectives. A literature review. Autoimmun Rev. 2023;22(6):103334.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"395_CR16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","volume":"7","author":"IE Lundberg","year":"2021","unstructured":"Lundberg IE, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Christopher-Stine L, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021;7(1):86.","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"395_CR17","doi-asserted-by":"publisher","first-page":"4792","DOI":"10.4049\/jimmunol.0803688","volume":"183","author":"AE Fasth","year":"2009","unstructured":"Fasth AE, Dastmalchi M, Rahbar A, Salomonsson S, Pandya JM, Lindroos E, et al. T cell infiltrates in the muscles of patients with dermatomyositis and polymyositis are dominated by CD28null T cells. J Immunol. 2009;183(7):4792\u20139.","journal-title":"J Immunol"},{"key":"395_CR18","doi-asserted-by":"publisher","first-page":"1328547","DOI":"10.3389\/fneur.2023.1328547","volume":"14","author":"HN Jeong","year":"2023","unstructured":"Jeong HN, Lee TG, Park HJ, Yang Y, Oh SH, Kang SW, et al. Transcriptome analysis of skeletal muscle in dermatomyositis, polymyositis, and dysferlinopathy, using a bioinformatics approach. Front Neurol. 2023;14:1328547.","journal-title":"Front Neurol"},{"key":"395_CR19","doi-asserted-by":"publisher","first-page":"1439807","DOI":"10.3389\/fimmu.2024.1439807","volume":"15","author":"Y Wu","year":"2024","unstructured":"Wu Y, Luo J, Duan L. Pathogenic mechanisms of disease in idiopathic inflammatory myopathies: autoantibodies as clues. Front Immunol. 2024;15:1439807.","journal-title":"Front Immunol"},{"issue":"6","key":"395_CR20","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1083\/jcb.200804077","volume":"183","author":"BS Cowling","year":"2008","unstructured":"Cowling BS, McGrath MJ, Nguyen MA, Cottle DL, Kee AJ, Brown S, et al. Identification of FHL1 as a regulator of skeletal muscle mass: implications for human myopathy. J Cell Biol. 2008;183(6):1033\u201348.","journal-title":"J Cell Biol"},{"issue":"12","key":"395_CR21","doi-asserted-by":"publisher","first-page":"4612","DOI":"10.1172\/JCI81031","volume":"125","author":"I Albrecht","year":"2015","unstructured":"Albrecht I, Wick C, Hallgren A, Tjarnlund A, Nagaraju K, Andrade F, et al. Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies. J Clin Invest. 2015;125(12):4612\u201324.","journal-title":"J Clin Invest"},{"issue":"10","key":"395_CR22","doi-asserted-by":"publisher","first-page":"4145","DOI":"10.1093\/rheumatology\/keac003","volume":"61","author":"AS Galindo-Feria","year":"2022","unstructured":"Galindo-Feria AS, Horuluoglu B, Day J, Fernandes-Cerqueira C, Wigren E, Graslund S, et al. Autoantibodies against four-and-a-half-LIM domain 1 (FHL1) in inflammatory myopathies: results from an Australian single-centre cohort. Rheumatology (Oxford). 2022;61(10):4145\u201354.","journal-title":"Rheumatology (Oxford)"},{"issue":"139","key":"395_CR23","doi-asserted-by":"publisher","first-page":"139ra85","DOI":"10.1126\/scitranslmed.3003921","volume":"4","author":"N Weisleder","year":"2012","unstructured":"Weisleder N, Takizawa N, Lin P, Wang X, Cao C, Zhang Y, et al. Recombinant MG53 protein modulates therapeutic cell membrane repair in treatment of muscular dystrophy. Sci Transl Med. 2012;4(139):139ra85.","journal-title":"Sci Transl Med"},{"issue":"4","key":"395_CR24","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/mt.2012.5","volume":"20","author":"B He","year":"2012","unstructured":"He B, Tang RH, Weisleder N, Xiao B, Yuan Z, Cai C, et al. Enhancing muscle membrane repair by gene delivery of MG53 ameliorates muscular dystrophy and heart failure in delta-Sarcoglycan-deficient hamsters. Mol Ther. 2012;20(4):727\u201335.","journal-title":"Mol Ther"},{"issue":"8","key":"395_CR25","first-page":"4440","volume":"130","author":"KE McElhanon","year":"2020","unstructured":"McElhanon KE, Young N, Hampton J, Paleo BJ, Kwiatkowski TA, Beck EX, et al. Autoantibodies targeting TRIM72 compromise membrane repair and contribute to inflammatory myopathy. J Clin Invest. 2020;130(8):4440\u201355.","journal-title":"J Clin Invest"},{"issue":"1","key":"395_CR26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1161\/CIRCRESAHA.109.215822","volume":"107","author":"X Wang","year":"2010","unstructured":"Wang X, Xie W, Zhang Y, Lin P, Han L, Han P, et al. Cardioprotection of ischemia\/reperfusion injury by cholesterol-dependent MG53-mediated membrane repair. Circ Res. 2010;107(1):76\u201383.","journal-title":"Circ Res"},{"issue":"1","key":"395_CR27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/ncb1812","volume":"11","author":"C Cai","year":"2009","unstructured":"Cai C, Masumiya H, Weisleder N, Matsuda N, Nishi M, Hwang M, et al. MG53 nucleates assembly of cell membrane repair machinery. Nat Cell Biol. 2009;11(1):56\u201364.","journal-title":"Nat Cell Biol"},{"issue":"7","key":"395_CR28","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1093\/rheumatology\/keaa801","volume":"60","author":"J Loarce-Martos","year":"2021","unstructured":"Loarce-Martos J, Lilleker JB, Parker M, McHugh N, Chinoy H. Polymyositis: is there anything left? A retrospective diagnostic review from a tertiary myositis centre. Rheumatology (Oxford). 2021;60(7):3398\u2013403.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"395_CR29","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1212\/WNL.61.3.316","volume":"61","author":"MF van der Meulen","year":"2003","unstructured":"van der Meulen MF, Bronner IM, Hoogendijk JE, Burger H, van Venrooij WJ, Voskuyl AE, et al. Polymyositis: an overdiagnosed entity. Neurology. 2003;61(3):316\u201321.","journal-title":"Neurology"},{"key":"395_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/biom12010111","author":"AH Opinc","year":"2022","unstructured":"Opinc AH, Makowska JS. Update on malignancy in myositis-well-established association with unmet needs. Biomolecules. 2022. https:\/\/doi.org\/10.3390\/biom12010111.","journal-title":"Biomolecules"},{"issue":"3","key":"395_CR31","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3109\/08916930903510955","volume":"43","author":"IE Lundberg","year":"2010","unstructured":"Lundberg IE, Helmers SB. The type I interferon system in idiopathic inflammatory myopathies. Autoimmunity. 2010;43(3):239\u201343.","journal-title":"Autoimmunity"},{"issue":"12","key":"395_CR32","doi-asserted-by":"publisher","first-page":"e1193","DOI":"10.1212\/WNL.0000000000008128","volume":"93","author":"I Pinal-Fernandez","year":"2019","unstructured":"Pinal-Fernandez I, Casal-Dominguez M, Derfoul A, Pak K, Plotz P, Miller FW, et al. Identification of distinctive interferon gene signatures in different types of myositis. Neurology. 2019;93(12):e1193\u2013204.","journal-title":"Neurology"},{"issue":"5","key":"395_CR33","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1136\/ard.2010.139949","volume":"70","author":"AP Liao","year":"2011","unstructured":"Liao AP, Salajegheh M, Nazareno R, Kagan JC, Jubin RG, Greenberg SA. Interferon beta is associated with type 1 interferon-inducible gene expression in dermatomyositis. Ann Rheum Dis. 2011;70(5):831\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"395_CR34","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1111\/bjd.15006","volume":"176","author":"C Huard","year":"2017","unstructured":"Huard C, Gulla SV, Bennett DV, Coyle AJ, Vleugels RA, Greenberg SA. Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon beta in dermatomyositis. Br J Dermatol. 2017;176(5):1224\u201330.","journal-title":"Br J Dermatol"},{"issue":"5","key":"395_CR35","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00401-021-02365-5","volume":"142","author":"DR Amici","year":"2021","unstructured":"Amici DR, Pinal-Fernandez I, Christopher-Stine L, Mammen AL, Mendillo ML. A network of core and subtype-specific gene expression programs in myositis. Acta Neuropathol. 2021;142(5):887\u201398.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"395_CR36","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/art.42972","volume":"77","author":"S Izuka","year":"2025","unstructured":"Izuka S, Umezawa N, Komai T, Sugimori Y, Kimura N, Mizoguchi F, et al. Muscle tissue transcriptome of idiopathic inflammatory myopathy reflects the muscle damage process by monocytes and presence of skin lesions. Arthritis Rheumatol. 2025;77(1):99\u2013106.","journal-title":"Arthritis Rheumatol"},{"key":"395_CR37","doi-asserted-by":"publisher","first-page":"1567833","DOI":"10.3389\/fimmu.2025.1567833","volume":"16","author":"S Izuka","year":"2025","unstructured":"Izuka S, Komai T, Tsuchida Y, Tsuchiya H, Okamura T, Fujio K. The role of monocytes and macrophages in idiopathic inflammatory myopathies: insights into pathogenesis and potential targets. Front Immunol. 2025;16:1567833.","journal-title":"Front Immunol"},{"issue":"10","key":"395_CR38","doi-asserted-by":"publisher","first-page":"e17240","DOI":"10.15252\/emmm.202217240","volume":"15","author":"A Argyriou","year":"2023","unstructured":"Argyriou A, Horuluoglu B, Galindo-Feria AS, Diaz-Boada JS, Sijbranda M, Notarnicola A, et al. Single-cell profiling of muscle-infiltrating T cells in idiopathic inflammatory myopathies. EMBO Mol Med. 2023;15(10):e17240.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"395_CR39","doi-asserted-by":"publisher","first-page":"6458","DOI":"10.1038\/s41467-022-34145-4","volume":"13","author":"Y Ye","year":"2022","unstructured":"Ye Y, Chen Z, Jiang S, Jia F, Li T, Lu X, et al. Single-cell profiling reveals distinct adaptive immune hallmarks in MDA5+ dermatomyositis with therapeutic implications. Nat Commun. 2022;13(1):6458.","journal-title":"Nat Commun"},{"issue":"8","key":"395_CR40","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1007\/s10067-023-06624-6","volume":"42","author":"P Zhang","year":"2023","unstructured":"Zhang P, Li M, Zhang Y, Lian C, Sun J, He Y, et al. Plasma proteomic profiling reveals KRT19 could be a potential biomarker in patients with anti-MDA5+ dermatomyositis. Clin Rheumatol. 2023;42(8):2145\u201354.","journal-title":"Clin Rheumatol"},{"key":"395_CR41","doi-asserted-by":"publisher","first-page":"6009","DOI":"10.2147\/JIR.S509777","volume":"18","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Hu W, Li T, Pan Z, Sun J, He Y, et al. Shared and distinctive inflammation-related protein profiling in idiopathic inflammatory myopathy with\/without anti-MDA5 autoantibodies. J Inflamm Res. 2025;18:6009\u201324.","journal-title":"J Inflamm Res"},{"issue":"4","key":"395_CR42","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0889-857X(02)00032-7","volume":"28","author":"IN Targoff","year":"2002","unstructured":"Targoff IN. Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies. Rheum Dis Clin North Am. 2002;28(4):859\u201390, viii.","journal-title":"Rheum Dis Clin North Am"},{"key":"395_CR43","doi-asserted-by":"publisher","first-page":"1436114","DOI":"10.3389\/fimmu.2024.1436114","volume":"15","author":"J Ding","year":"2024","unstructured":"Ding J, Li Y, Wang Z, Han F, Chen M, Du J, et al. A distinct immune landscape in anti-synthetase syndrome profiled by a single-cell genomic study. Front Immunol. 2024;15:1436114.","journal-title":"Front Immunol"},{"issue":"10","key":"395_CR44","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1136\/jnnp.2007.131334","volume":"79","author":"CC Weihl","year":"2008","unstructured":"Weihl CC, Temiz P, Miller SE, Watts G, Smith C, Forman M, et al. TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2008;79(10):1186\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"395_CR45","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.expneurol.2018.08.006","volume":"309","author":"N Tawara","year":"2018","unstructured":"Tawara N, Yamashita S, Kawakami K, Kurashige T, Zhang Z, Tasaki M, et al. Muscle-dominant wild-type TDP-43 expression induces myopathological changes featuring tubular aggregates and TDP-43-positive inclusions. Exp Neurol. 2018;309:169\u201380.","journal-title":"Exp Neurol"},{"issue":"628","key":"395_CR46","doi-asserted-by":"publisher","first-page":"eabi9196","DOI":"10.1126\/scitranslmed.abi9196","volume":"14","author":"KA Britson","year":"2022","unstructured":"Britson KA, Ling JP, Braunstein KE, Montagne JM, Kastenschmidt JM, Wilson A, et al. Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis. Sci Transl Med. 2022;14(628):eabi9196.","journal-title":"Sci Transl Med"},{"issue":"7","key":"395_CR47","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s43587-024-00645-9","volume":"4","author":"S Wischnewski","year":"2024","unstructured":"Wischnewski S, Thawel T, Ikenaga C, Kocharyan A, Lerma-Martin C, Zulji A, et al. Cell type mapping of inflammatory muscle diseases highlights selective myofiber vulnerability in inclusion body myositis. Nat Aging. 2024;4(7):969\u201383.","journal-title":"Nat Aging"},{"issue":"1","key":"395_CR48","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s41232-025-00369-2","volume":"45","author":"AT Miyamoto","year":"2025","unstructured":"Miyamoto AT, Shimagami H, Kumanogoh A, Nishide M. Spatial transcriptomics in autoimmune rheumatic disease: potential clinical applications and perspectives. Inflamm Regen. 2025;45(1):6.","journal-title":"Inflamm Regen"},{"issue":"10","key":"395_CR49","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1093\/jnen\/nlac067","volume":"81","author":"S Matsubara","year":"2022","unstructured":"Matsubara S, Suzuki S, Komori T. Immunohistochemical phenotype of T cells invading muscle in inclusion body myositis. J Neuropathol Exp Neurol. 2022;81(10):825\u201335.","journal-title":"J Neuropathol Exp Neurol"},{"key":"395_CR50","unstructured":"NIH. A phase 1 study of ABC008 in ascending (single ascending dose\/multiple ascending dose) study in patients with (IBM). 2023. https:\/\/clinicaltrials.gov\/study\/NCT04659031"},{"issue":"5","key":"395_CR51","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","volume":"14","author":"JE Hoogendijk","year":"2004","unstructured":"Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10\u201312 October 2003, Naarden, The Netherlands. Neuromuscul Disord. 2004;14(5):337\u201345.","journal-title":"Neuromuscul Disord"},{"key":"395_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23084301","author":"RG Kamperman","year":"2022","unstructured":"Kamperman RG, van der Kooi AJ, de Visser M, Aronica E, Raaphorst J. Pathophysiological mechanisms and treatment of dermatomyositis and immune mediated necrotizing myopathies: a focused review. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23084301.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"395_CR53","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1136\/jnnp-2016-313166","volume":"87","author":"Y Watanabe","year":"2016","unstructured":"Watanabe Y, Uruha A, Suzuki S, Nakahara J, Hamanaka K, Takayama K, et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry. 2016;87(10):1038\u201344.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"395_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10082036","author":"S Julien","year":"2022","unstructured":"Julien S, Vadysirisack D, Sayegh C, Ragunathan S, Tang Y, Briand E, et al. Prevention of anti-HMGCR immune-mediated necrotising myopathy by C5 complement inhibition in a humanised mouse model. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10082036.","journal-title":"Biomedicines"},{"issue":"2","key":"395_CR55","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.yexmp.2005.06.008","volume":"79","author":"AK McNally","year":"2005","unstructured":"McNally AK, Anderson JM. Multinucleated giant cell formation exhibits features of phagocytosis with participation of the endoplasmic reticulum. Exp Mol Pathol. 2005;79(2):126\u201335.","journal-title":"Exp Mol Pathol"},{"key":"395_CR56","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.134189","author":"N Seto","year":"2020","unstructured":"Seto N, Torres-Ruiz JJ, Carmona-Rivera C, Pinal-Fernandez I, Pak K, Purmalek MM, et al. Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies. JCI Insight. 2020. https:\/\/doi.org\/10.1172\/jci.insight.134189.","journal-title":"JCI Insight"},{"issue":"1","key":"395_CR57","doi-asserted-by":"publisher","first-page":"26","DOI":"10.4046\/trd.2024.0072","volume":"88","author":"M Moda","year":"2025","unstructured":"Moda M, Yanagihara T, Nakashima R, Sumikawa H, Shimizu S, Arai T, et al. Idiopathic inflammatory myopathies-associated interstitial lung disease in adults. Tuberculosis Respir Dis. 2025;88(1):26\u201344.","journal-title":"Tuberculosis Respir Dis"},{"issue":"5","key":"395_CR58","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","volume":"14","author":"NJ McHugh","year":"2018","unstructured":"McHugh NJ, Tansley SL. Autoantibodies in myositis. Nat Rev Rheumatol. 2018;14(5):290\u2013302.","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"395_CR59","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1080\/25785826.2018.1531188","volume":"41","author":"R Nakashima","year":"2018","unstructured":"Nakashima R. Clinical significance of myositis-specific autoantibodies. Immunol Med. 2018;41(3):103\u201312.","journal-title":"Immunol Med"},{"issue":"7","key":"395_CR60","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/art.24621","volume":"60","author":"S Sato","year":"2009","unstructured":"Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009;60(7):2193\u2013200.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"395_CR61","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/art.41554","volume":"73","author":"M Nakazawa","year":"2021","unstructured":"Nakazawa M, Suzuki K, Takeshita M, Inamo J, Kamata H, Ishii M, et al. Distinct expression of coinhibitory molecules on alveolar T cells in patients with rheumatoid arthritis-associated and idiopathic inflammatory myopathy-associated interstitial lung disease. Arthritis Rheumatol. 2021;73(4):576\u201386.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"395_CR62","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1046\/j.1365-2249.2002.01933.x","volume":"129","author":"K Kurasawa","year":"2002","unstructured":"Kurasawa K, Nawata Y, Takabayashi K, Kumano K, Kita Y, Takiguchi Y, et al. Activation of pulmonary T cells in corticosteroid-resistant and -sensitive interstitial pneumonitis in dermatomyositis\/polymyositis. Clin Exp Immunol. 2002;129(3):541\u20138.","journal-title":"Clin Exp Immunol"},{"key":"395_CR63","doi-asserted-by":"publisher","first-page":"1145814","DOI":"10.3389\/fimmu.2023.1145814","volume":"14","author":"K Hata","year":"2023","unstructured":"Hata K, Yanagihara T, Matsubara K, Kunimura K, Suzuki K, Tsubouchi K, et al. Mass cytometry identifies characteristic immune cell subsets in bronchoalveolar lavage fluid from interstitial lung diseases. Front Immunol. 2023;14:1145814.","journal-title":"Front Immunol"},{"issue":"2","key":"395_CR64","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1016\/S2665-9913(23)00322-3","volume":"6","author":"CM Connolly","year":"2024","unstructured":"Connolly CM, Gupta L, Fujimoto M, Machado PM, Paik JJ. Idiopathic inflammatory myopathies: current insights and future frontiers. Lancet Rheumatol. 2024;6(2):e115\u201327.","journal-title":"Lancet Rheumatol"},{"issue":"14","key":"395_CR65","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","volume":"387","author":"R Aggarwal","year":"2022","unstructured":"Aggarwal R, Charles-Schoeman C, Schessl J, Bata-Csorgo Z, Dimachkie MM, Griger Z, et al. Trial of intravenous immune globulin in dermatomyositis. N Engl J Med. 2022;387(14):1264\u201378.","journal-title":"N Engl J Med"},{"key":"395_CR66","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01488-2024","author":"W Wu","year":"2025","unstructured":"Wu W, Guo B, Sun W, Chen D, Xu W, Chen Z, et al. Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort study. Eur Respir J. 2025. https:\/\/doi.org\/10.1183\/13993003.01488-2024.","journal-title":"Eur Respir J"},{"issue":"Suppl 1","key":"395_CR67","doi-asserted-by":"publisher","first-page":"e000784","DOI":"10.1136\/rmdopen-2018-000784","volume":"4","author":"A Meyer","year":"2018","unstructured":"Meyer A, Scire CA, Talarico R, Alexander T, Amoura Z, Avcin T, et al. Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines [corrected]. RMD Open. 2018;4(Suppl 1):e000784.","journal-title":"RMD Open"},{"issue":"1","key":"395_CR68","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/rheumatology\/kel112","volume":"46","author":"Y Yamasaki","year":"2007","unstructured":"Yamasaki Y, Yamada H, Yamasaki M, Ohkubo M, Azuma K, Matsuoka S, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis\/dermatomyositis. Rheumatology (Oxford). 2007;46(1):124\u201330.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"395_CR69","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1002\/art.21240","volume":"52","author":"MR Wilkes","year":"2005","unstructured":"Wilkes MR, Sereika SM, Fertig N, Lucas MR, Oddis CV. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum. 2005;52(8):2439\u201346.","journal-title":"Arthritis Rheum"},{"key":"395_CR70","doi-asserted-by":"crossref","unstructured":"Trallero-Araguas E, Rodrigo-Pendas JA, Selva-O\u2019Callaghan A, Martinez-Gomez X, Bosch X, Labrador-Horrillo M, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523-32.","DOI":"10.1002\/art.33379"},{"key":"395_CR71","unstructured":"Yasir M, Goyal A, Sonthalia S. Corticosteroid Adverse Effects. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Amandeep Goyal declares no relevant financial relationships with ineligible companies. Disclosure: Sidharth Sonthalia declares no relevant financial relationships with ineligible companies.2025."},{"issue":"2","key":"395_CR72","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/art.37754","volume":"65","author":"CV Oddis","year":"2013","unstructured":"Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65(2):314\u201324.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"395_CR73","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1001\/jamadermatol.2023.4744","volume":"160","author":"KS Shaw","year":"2024","unstructured":"Shaw KS, Reusch DB, Castillo RL, Hashemi KB, Sundel R, Dedeoglu F, et al. Rapid improvement in recalcitrant cutaneous juvenile dermatomyositis with anifrolumab treatment. JAMA Dermatol. 2024;160(2):237\u20138.","journal-title":"JAMA Dermatol"},{"issue":"10473","key":"395_CR74","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0140-6736(24)02071-3","volume":"405","author":"D Fiorentino","year":"2025","unstructured":"Fiorentino D, Mangold AR, Werth VP, Christopher-Stine L, Femia A, Chu M, et al. Efficacy, safety, and target engagement of dazukibart, an IFNbeta specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2025;405(10473):137\u201346.","journal-title":"Lancet"},{"issue":"2","key":"395_CR75","first-page":"354","volume":"43","author":"JJ Paik","year":"2025","unstructured":"Paik JJ, Vencovsky J, Charles-Schoeman C, Wright GC, Vleugels RA, Goriounova AS, et al. Brepocitinib, a potent and selective TYK2\/JAK1 inhibitor: scientific and clinical rationale for dermatomyositis. Clin Exp Rheumatol. 2025;43(2):354\u201363.","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"395_CR76","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1080\/1744666X.2023.2212162","volume":"19","author":"CM Connolly","year":"2023","unstructured":"Connolly CM, Paik JJ. Clinical pearls and promising therapies in myositis. Expert Rev Clin Immunol. 2023;19(7):797\u2013811.","journal-title":"Expert Rev Clin Immunol"},{"key":"395_CR77","doi-asserted-by":"publisher","first-page":"1560483","DOI":"10.3389\/fneur.2025.1560483","volume":"16","author":"Q Peng","year":"2025","unstructured":"Peng Q, Yao X, Chen S, Li X, Lin F, Zou Z. Efgartigimod combined with steroids as a fast-acting therapy for anti-SRP immune-mediated necrotizing myopathy. Front Neurol. 2025;16:1560483.","journal-title":"Front Neurol"},{"issue":"6","key":"395_CR78","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40263-024-01090-3","volume":"38","author":"N Alfaidi","year":"2024","unstructured":"Alfaidi N, Karmastaji S, Matic A, Bril V. FcRn inhibitor therapies in neurologic diseases. CNS Drugs. 2024;38(6):425\u201341.","journal-title":"CNS Drugs"},{"key":"395_CR79","unstructured":"NIH. A study to evaluate safety and efficacy of empasiprubart in adults with dermatomyositis (empacific). 2024.\u00a0https:\/\/clinicaltrials.gov\/study\/NCT06284954"},{"issue":"6","key":"395_CR80","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3899\/jrheum.2024-1115","volume":"52","author":"A Aggarwal","year":"2025","unstructured":"Aggarwal A, Almackenzie M, Aggarwal R. Role of CD19 chimeric antigen receptor T cell therapy in idiopathic inflammatory myopathies. J Rheumatol. 2025;52(6):532\u201342.","journal-title":"J Rheumatol"},{"issue":"2","key":"395_CR81","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41584-024-01210-9","volume":"21","author":"M Stockfelt","year":"2025","unstructured":"Stockfelt M, Teng YKO, Vital EM. Opportunities and limitations of B cell depletion approaches in SLE. Nat Rev Rheumatol. 2025;21(2):111\u201326.","journal-title":"Nat Rev Rheumatol"},{"key":"395_CR82","doi-asserted-by":"crossref","unstructured":"Patil H, Bharadwaj RK, Dutta N, Subramanian R, Prasad S, Mamadapur M. CAR-T cell therapy in rheumatic diseases: a review article. Clin Rheumatol. 2025.","DOI":"10.1007\/s10067-025-07451-7"},{"issue":"4","key":"395_CR83","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1002\/art.22521","volume":"56","author":"T Sugihara","year":"2007","unstructured":"Sugihara T, Sekine C, Nakae T, Kohyama K, Harigai M, Iwakura Y, et al. A new murine model to define the critical pathologic and therapeutic mediators of polymyositis. Arthritis Rheum. 2007;56(4):1304\u201314.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"395_CR84","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1136\/annrheumdis-2020-218661","volume":"80","author":"N Okiyama","year":"2021","unstructured":"Okiyama N, Ichimura Y, Shobo M, Tanaka R, Kubota N, Saito A, et al. Immune response to dermatomyositis-specific autoantigen, transcriptional intermediary factor 1gamma can result in experimental myositis. Ann Rheum Dis. 2021;80(9):1201\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"395_CR85","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/25785826.2022.2137968","volume":"46","author":"R Konishi","year":"2023","unstructured":"Konishi R, Ichimura Y, Okiyama N. Murine models of idiopathic inflammatory myopathy. Immunol Med. 2023;46(1):9\u201314.","journal-title":"Immunol Med"},{"issue":"1","key":"395_CR86","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3181\/00379727-91-22179","volume":"91","author":"CM Pearson","year":"1956","unstructured":"Pearson CM. Development of arthritis, periarthritis and periostitis in rats given adjuvants. Proc Soc Exp Biol Med. 1956;91(1):95\u2013101.","journal-title":"Proc Soc Exp Biol Med"},{"issue":"2\u20133","key":"395_CR87","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jaut.2007.07.005","volume":"29","author":"Y Katsumata","year":"2007","unstructured":"Katsumata Y, Ridgway WM, Oriss T, Gu X, Chin D, Wu Y, et al. Species-specific immune responses generated by histidyl-tRNA synthetase immunization are associated with muscle and lung inflammation. J Autoimmun. 2007;29(2\u20133):174\u201386.","journal-title":"J Autoimmun"},{"issue":"16","key":"395_CR88","doi-asserted-by":"publisher","first-page":"e2313070121","DOI":"10.1073\/pnas.2313070121","volume":"121","author":"Y Ichimura","year":"2024","unstructured":"Ichimura Y, Konishi R, Shobo M, Tanaka R, Kubota N, Kayama H, et al. Autoimmunity against melanoma differentiation-associated gene 5 induces interstitial lung disease mimicking dermatomyositis in mice. Proc Natl Acad Sci U S A. 2024;121(16):e2313070121.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"395_CR89","doi-asserted-by":"publisher","DOI":"10.1093\/cei\/uxae106","author":"L Bai","year":"2025","unstructured":"Bai L, Zhu J, Ma W, Zhao P, Li F, Zhang C, et al. A novel mouse model of myositis-associated interstitial lung disease was established by using TLR9 agonist combined with muscle homogenate. Clin Exp Immunol. 2025. https:\/\/doi.org\/10.1093\/cei\/uxae106.","journal-title":"Clin Exp Immunol"},{"issue":"9","key":"395_CR90","doi-asserted-by":"publisher","first-page":"6334","DOI":"10.1073\/pnas.082545599","volume":"99","author":"MC Sugarman","year":"2002","unstructured":"Sugarman MC, Yamasaki TR, Oddo S, Echegoyen JC, Murphy MP, Golde TE, et al. Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. Proc Natl Acad Sci U S A. 2002;99(9):6334\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"27","key":"395_CR91","doi-asserted-by":"publisher","first-page":"11125","DOI":"10.1073\/pnas.0811753106","volume":"106","author":"LJ Page","year":"2009","unstructured":"Page LJ, Suk JY, Bazhenova L, Fleming SM, Wood M, Jiang Y, et al. Secretion of amyloidogenic gelsolin progressively compromises protein homeostasis leading to the intracellular aggregation of proteins. Proc Natl Acad Sci U S A. 2009;106(27):11125\u201330.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"395_CR92","doi-asserted-by":"publisher","first-page":"103131","DOI":"10.1016\/j.jaut.2023.103131","volume":"142","author":"H Sasaki","year":"2024","unstructured":"Sasaki H, Umezawa N, Itakura T, Iwai H, Yasuda S. Pathogenicity of functionally activated PD-1(+)CD8(+) cells and counterattacks by muscular PD-L1 through IFNgamma in myositis. J Autoimmun. 2024;142:103131.","journal-title":"J Autoimmun"},{"issue":"10","key":"395_CR93","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1002\/art.27625","volume":"62","author":"T Sugihara","year":"2010","unstructured":"Sugihara T, Okiyama N, Suzuki M, Kohyama K, Matsumoto Y, Miyasaka N, et al. Definitive engagement of cytotoxic CD8 T cells in C protein-induced myositis, a murine model of polymyositis. Arthritis Rheum. 2010;62(10):3088\u201392.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"395_CR94","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1002\/art.24689","volume":"60","author":"N Okiyama","year":"2009","unstructured":"Okiyama N, Sugihara T, Iwakura Y, Yokozeki H, Miyasaka N, Kohsaka H. Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A. Arthritis Rheum. 2009;60(8):2505\u201312.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"395_CR95","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1002\/art.34465","volume":"64","author":"T Sugihara","year":"2012","unstructured":"Sugihara T, Okiyama N, Watanabe N, Miyasaka N, Kohsaka H. Interleukin-1 and tumor necrosis factor alpha blockade treatment of experimental polymyositis in mice. Arthritis Rheum. 2012;64(8):2655\u201362.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"395_CR96","doi-asserted-by":"publisher","first-page":"5498","DOI":"10.1038\/s41598-018-23539-4","volume":"8","author":"N Umezawa","year":"2018","unstructured":"Umezawa N, Kawahata K, Mizoguchi F, Kimura N, Yoshihashi-Nakazato Y, Miyasaka N, et al. Interleukin-23 as a therapeutic target for inflammatory myopathy. Sci Rep. 2018;8(1):5498.","journal-title":"Sci Rep"},{"issue":"3","key":"395_CR97","doi-asserted-by":"publisher","first-page":"R126","DOI":"10.1186\/ar4583","volume":"16","author":"J Kim","year":"2014","unstructured":"Kim J, Choi JY, Park SH, Yang SH, Park JA, Shin K, et al. Therapeutic effect of anti-C-X-C motif chemokine 10 (CXCL10) antibody on C protein-induced myositis mouse. Arthritis Res Ther. 2014;16(3):R126.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"395_CR98","first-page":"593","volume":"35","author":"H Hasegawa","year":"2017","unstructured":"Hasegawa H, Kawahata K, Mizoguchi F, Okiyama N, Miyasaka N, Kohsaka H. Direct suppression of autoaggressive CD8+ T cells with CD80\/86 blockade in CD8+ T cell-mediated polymyositis models of mice. Clin Exp Rheumatol. 2017;35(4):593\u20137.","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"395_CR99","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1002\/eji.202249851","volume":"52","author":"M Del Rio Oliva","year":"2022","unstructured":"Del Rio Oliva M, Kirk CJ, Groettrup M, Basler M. Effective therapy of polymyositis in mice via selective inhibition of the immunoproteasome. Eur J Immunol. 2022;52(9):1510\u201322.","journal-title":"Eur J Immunol"},{"issue":"1","key":"395_CR100","first-page":"117","volume":"68","author":"NL Rosenberg","year":"1987","unstructured":"Rosenberg NL, Ringel SP, Kotzin BL. Experimental autoimmune myositis in SJL\/J mice. Clin Exp Immunol. 1987;68(1):117\u201329.","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"395_CR101","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1293\/tox.25.135","volume":"25","author":"K Kobayashi","year":"2012","unstructured":"Kobayashi K, Izawa T, Kuwamura M, Yamate J. Dysferlin and animal models for dysferlinopathy. J Toxicol Pathol. 2012;25(2):135\u201347.","journal-title":"J Toxicol Pathol"},{"issue":"3","key":"395_CR102","doi-asserted-by":"publisher","first-page":"989","DOI":"10.2353\/ajpath.2009.080422","volume":"174","author":"Y Allenbach","year":"2009","unstructured":"Allenbach Y, Solly S, Gregoire S, Dubourg O, Salomon B, Butler-Browne G, et al. Role of regulatory T cells in a new mouse model of experimental autoimmune myositis. Am J Pathol. 2009;174(3):989\u201398.","journal-title":"Am J Pathol"},{"issue":"22","key":"395_CR103","doi-asserted-by":"publisher","first-page":"6189","DOI":"10.1113\/JP286534","volume":"602","author":"K Himori","year":"2024","unstructured":"Himori K, Yamada M, Onoki T, Matsumaru D, Motohashi H, Okutsu M. Nrf2 deficiency in muscle attenuates experimental autoimmune myositis-induced muscle weakness. J Physiol. 2024;602(22):6189\u2013207.","journal-title":"J Physiol"},{"issue":"11","key":"395_CR104","first-page":"14457","volume":"8","author":"J Kang","year":"2015","unstructured":"Kang J, Zhang HY, Feng GD, Feng DY, Jia HG. Development of an improved animal model of experimental autoimmune myositis. Int J Clin Exp Pathol. 2015;8(11):14457\u201364.","journal-title":"Int J Clin Exp Pathol"},{"issue":"12","key":"395_CR105","doi-asserted-by":"publisher","first-page":"4289","DOI":"10.4049\/jimmunol.142.12.4289","volume":"142","author":"NL Rosenberg","year":"1989","unstructured":"Rosenberg NL, Kotzin BL. Aberrant expression of class II MHC antigens by skeletal muscle endothelial cells in experimental autoimmune myositis. J Immunol. 1989;142(12):4289\u201394.","journal-title":"J Immunol"},{"issue":"1","key":"395_CR106","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0022-510X(01)00635-9","volume":"193","author":"H Nemoto","year":"2001","unstructured":"Nemoto H, Nemoto K, Sugimoto H, Kinoshita M. FK506 suppressed the inflammatory change of EAM in SJL\/J mice. J Neurol Sci. 2001;193(1):7\u201311.","journal-title":"J Neurol Sci"},{"issue":"3","key":"395_CR107","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/mus.10042","volume":"25","author":"T Ito","year":"2002","unstructured":"Ito T, Kumamoto T, Horinouchi H, Yukishige K, Sugihara R, Fujimoto S, et al. Adhesion molecule expression in experimental myositis. Muscle Nerve. 2002;25(3):409\u201318.","journal-title":"Muscle Nerve"},{"issue":"2","key":"395_CR108","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1046\/j.1365-2249.2001.01499.x","volume":"124","author":"J Wada","year":"2001","unstructured":"Wada J, Shintani N, Kikutani K, Nakae T, Yamauchi T, Takechi K. Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition. Clin Exp Immunol. 2001;124(2):282\u20139.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"395_CR109","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3892\/etm.2020.8716","volume":"20","author":"J Kang","year":"2020","unstructured":"Kang J, Feng D, Yang F, Tian X, Han W, Jia H. Comparison of rapamycin and methylprednisolone for treating inflammatory muscle disease in a murine model of experimental autoimmune myositis. Exp Ther Med. 2020;20(1):219\u201326.","journal-title":"Exp Ther Med"},{"issue":"10","key":"395_CR110","doi-asserted-by":"publisher","first-page":"6987","DOI":"10.4049\/jimmunol.175.10.6987","volume":"175","author":"F Suzuki","year":"2005","unstructured":"Suzuki F, Nanki T, Imai T, Kikuchi H, Hirohata S, Kohsaka H, et al. Inhibition of CX3CL1 (fractalkine) improves experimental autoimmune myositis in SJL\/J mice. J Immunol. 2005;175(10):6987\u201396.","journal-title":"J Immunol"},{"issue":"10","key":"395_CR111","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1002\/art.24930","volume":"60","author":"N Ohyanagi","year":"2009","unstructured":"Ohyanagi N, Ishido M, Suzuki F, Kaneko K, Kubota T, Miyasaka N, et al. Retinoid ameliorates experimental autoimmune myositis, with modulation of Th cell differentiation and antibody production in vivo. Arthritis Rheum. 2009;60(10):3118\u201327.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"395_CR112","doi-asserted-by":"publisher","first-page":"e74450","DOI":"10.1371\/journal.pone.0074450","volume":"8","author":"N Prevel","year":"2013","unstructured":"Prevel N, Allenbach Y, Klatzmann D, Salomon B, Benveniste O. Beneficial role of rapamycin in experimental autoimmune myositis. PLoS ONE. 2013;8(11):e74450.","journal-title":"PLoS ONE"},{"issue":"2","key":"395_CR113","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/art.33403","volume":"64","author":"M Fujimoto","year":"2012","unstructured":"Fujimoto M, Hamaguchi Y, Kaji K, Matsushita T, Ichimura Y, Kodera M, et al. Myositis-specific anti-155\/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum. 2012;64(2):513\u201322.","journal-title":"Arthritis Rheum"},{"issue":"16","key":"395_CR114","doi-asserted-by":"publisher","first-page":"9209","DOI":"10.1073\/pnas.97.16.9209","volume":"97","author":"K Nagaraju","year":"2000","unstructured":"Nagaraju K, Raben N, Loeffler L, Parker T, Rochon PJ, Lee E, et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci U S A. 2000;97(16):9209\u201314.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"395_CR115","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/0046-8177(89)90128-7","volume":"20","author":"AM Emslie-Smith","year":"1989","unstructured":"Emslie-Smith AM, Arahata K, Engel AG. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol. 1989;20(3):224\u201331.","journal-title":"Hum Pathol"},{"issue":"6","key":"395_CR116","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1002\/art.21103","volume":"52","author":"K Nagaraju","year":"2005","unstructured":"Nagaraju K, Casciola-Rosen L, Lundberg I, Rawat R, Cutting S, Thapliyal R, et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum. 2005;52(6):1824\u201335.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"395_CR117","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.2353\/ajpath.2006.051232","volume":"168","author":"M Kitazawa","year":"2006","unstructured":"Kitazawa M, Green KN, Caccamo A, LaFerla FM. Genetically augmenting Abeta42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice. Am J Pathol. 2006;168(6):1986\u201397.","journal-title":"Am J Pathol"},{"issue":"Pt 21","key":"395_CR118","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1242\/jcs.00817","volume":"116","author":"PG Woodman","year":"2003","unstructured":"Woodman PG. p97, a protein coping with multiple identities. J Cell Sci. 2003;116(Pt 21):4283\u201390.","journal-title":"J Cell Sci"},{"issue":"4","key":"395_CR119","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/ng1332","volume":"36","author":"GD Watts","year":"2004","unstructured":"Watts GD, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet. 2004;36(4):377\u201381.","journal-title":"Nat Genet"},{"issue":"8","key":"395_CR120","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1093\/hmg\/ddm037","volume":"16","author":"CC Weihl","year":"2007","unstructured":"Weihl CC, Miller SE, Hanson PI, Pestronk A. Transgenic expression of inclusion body myopathy associated mutant p97\/VCP causes weakness and ubiquitinated protein inclusions in mice. Hum Mol Genet. 2007;16(8):919\u201328.","journal-title":"Hum Mol Genet"},{"issue":"2","key":"395_CR121","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/mus.23522","volume":"47","author":"A Nalbandian","year":"2013","unstructured":"Nalbandian A, Llewellyn KJ, Badadani M, Yin HZ, Nguyen C, Katheria V, et al. A progressive translational mouse model of human valosin-containing protein disease: the VCP(R155H\/+) mouse. Muscle Nerve. 2013;47(2):260\u201370.","journal-title":"Muscle Nerve"},{"issue":"9","key":"395_CR122","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1093\/hmg\/ddq050","volume":"19","author":"SK Custer","year":"2010","unstructured":"Custer SK, Neumann M, Lu H, Wright AC, Taylor JP. Transgenic mice expressing mutant forms VCP\/p97 recapitulate the full spectrum of IBMPFD including degeneration in muscle, brain and bone. Hum Mol Genet. 2010;19(9):1741\u201355.","journal-title":"Hum Mol Genet"},{"issue":"2","key":"395_CR123","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/infdis\/140.2.239","volume":"140","author":"CG Ray","year":"1979","unstructured":"Ray CG, Minnich LL, Johnson PC. Selective polymyositis inducted by coxsackievirus B1 in mice. J Infect Dis. 1979;140(2):239\u201343.","journal-title":"J Infect Dis"},{"issue":"1","key":"395_CR124","first-page":"12","volume":"14","author":"SR Ytterberg","year":"1987","unstructured":"Ytterberg SR. Coxsackievirus B 1 induced murine polymyositis: acute infection with active virus is required for myositis. J Rheumatol. 1987;14(1):12\u20138.","journal-title":"J Rheumatol"},{"issue":"2","key":"395_CR125","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1128\/JVI.80.2.737-749.2006","volume":"80","author":"TE Morrison","year":"2006","unstructured":"Morrison TE, Whitmore AC, Shabman RS, Lidbury BA, Mahalingam S, Heise MT. Characterization of Ross River virus tropism and virus-induced inflammation in a mouse model of viral arthritis and myositis. J Virol. 2006;80(2):737\u201349.","journal-title":"J Virol"},{"issue":"1","key":"395_CR126","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ajpath.2010.11.018","volume":"178","author":"TE Morrison","year":"2011","unstructured":"Morrison TE, Oko L, Montgomery SA, Whitmore AC, Lotstein AR, Gunn BM, et al. A mouse model of chikungunya virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis, and persistence. Am J Pathol. 2011;178(1):32\u201340.","journal-title":"Am J Pathol"},{"issue":"1","key":"395_CR127","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1136\/annrheumdis-2018-213518","volume":"78","author":"C Bergua","year":"2019","unstructured":"Bergua C, Chiavelli H, Allenbach Y, Arouche-Delaperche L, Arnoult C, Bourdenet G, et al. In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy. Ann Rheum Dis. 2019;78(1):131\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"395_CR128","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1093\/rheumatology\/kead298","volume":"62","author":"S Julien","year":"2023","unstructured":"Julien S, van der Woning B, De Ceuninck L, Briand E, Jaworski T, Roussel G, et al. Efgartigimod restores muscle function in a humanized mouse model of immune-mediated necrotizing myopathy. Rheumatology (Oxford). 2023;62(12):4006\u201311.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"395_CR129","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1002\/art.22865","volume":"56","author":"KB Stone","year":"2007","unstructured":"Stone KB, Oddis CV, Fertig N, Katsumata Y, Lucas M, Vogt M, et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum. 2007;56(9):3125\u201331.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"395_CR130","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13075-023-03116-5","volume":"25","author":"R Arcani","year":"2023","unstructured":"Arcani R, Rey L, Mazziotto A, Bertin D, Kaplanski G, Jarrot PA, et al. Anti-Jo-1 autoantibodies: biomarkers of severity and evolution of the disease in antisynthetase syndrome. Arthritis Res Ther. 2023;25(1):125.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"395_CR131","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1002\/art.21023","volume":"52","author":"S Sato","year":"2005","unstructured":"Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52(5):1571\u20136.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"395_CR132","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41232-025-00365-6","volume":"45","author":"A Nishidate","year":"2025","unstructured":"Nishidate A, Takemoto K, Imura Y, Murase M, Yamanaka R, Kikuchi M, et al. Human PBMC-based humanized mice exhibit myositis features and serve as a drug evaluation model. Inflamm Regen. 2025;45(1):1.","journal-title":"Inflamm Regen"}],"container-title":["Inflammation and Regeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41232-025-00395-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41232-025-00395-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41232-025-00395-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:01:46Z","timestamp":1760004106000},"score":1,"resource":{"primary":{"URL":"https:\/\/inflammregen.biomedcentral.com\/articles\/10.1186\/s41232-025-00395-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":132,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["395"],"URL":"https:\/\/doi.org\/10.1186\/s41232-025-00395-0","relation":{},"ISSN":["1880-8190"],"issn-type":[{"value":"1880-8190","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"assertion":[{"value":"10 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors are employees of Mitsubishi Tanabe Pharma Corporation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}